Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT01046422 | Safety Study of BMS-770767 in Subjects With Type 2 Diabetes | PHASE2 | COMPLETED | 76 | — | — | May 1, 2010 | Jan 1, 2011 | Oct 12, 2015 | 18 | United States, Australia +2 |
| Arm | Type | Description |
|---|---|---|
| BMS-770767 ± metformin (Treatment A) | EXPERIMENTAL | - |
| BMS-770767 ± metformin (Treatment B) | EXPERIMENTAL | - |
| BMS-770767 ± metformin (Treatment C) | EXPERIMENTAL | - |
| BMS-770767 ± metformin (Treatment D) | EXPERIMENTAL | - |
| Placebo ± metformin (Treatment E) | PLACEBO_COMPARATOR | - |
| Name | Type | Description |
|---|---|---|
| BMS-770767 | DRUG | Capsule, Oral, 15mg, Active, Daily, 28 days |
| Placebo | DRUG | Capsule, Oral, 0mg, Daily, 28 days |
| Metformin | DRUG | Tablet, Oral, ≥ 1500mg, Active, Daily, 28 days |
Inclusion Criteria: * Diagnosed with type 2 diabetes with inadequate glycemic control and treated with either diet and exercise alone, or with stable doses (≥ 1500mg/d) of metformin for at least 8 weeks prior to screening * HbA1c ≥ 7.0% and ≤ 10.0% with FPG ≤ 240mg/dL (13.3 mmol/dL) Exclusion Crit...